ID	1.1.1.1

IN	#2,4,5,8,27,34,36,38# more (#8# high ionic strength inhibits the enzyme
	to a higher extent when NADPH instead of NADH is used as a cofactor
	<17>; #5# model of inhibitor binding interactions <34>; #5,8# scarcely
	inhibitory: sorbinil <44>; #4# aldose reductase inhibitors have
	considerable potential for the treatment of diabetes, without increased
	risk of hypoglycemia, structure-activity relationship study, the
	applicable side alkyl chain length and the presence of a OCH3 group at
	C3 in the aromatic ring are essential features for enzyme recognition
	and binding, no or poor inhibition by gingerol, shogaol,
	2-(4-hydroxy-3-nitrophenyl)ethanoic acid,
	2-(3,4-dihydroxyphenyl)ethanoic acid, and 2-(4-hydroxyphenyl)ethanoic
	acid <71>; #5# enzyme inhibition counteracts nitrosative stress and
	poly(ADP-ribose) polymerase activation in diabetic kidney cortex <69>;
	#4# enzyme inhibition counteracts nitrosative stress and
	poly(ADP-ribose) polymerase activation in high-glucose exposed
	mesengial cells <69>; #4# enzyme-inhibitor complex structures, the
	hydrophobic nature of the enzyme active site makes significant
	contributions to inhibitor binding rather than a reliance on pi-pi
	orbital interactions with Trp 20, overview <60>; #4,5# inhibition of AR
	protects the ischemic myocardium and is associated with improved energy
	metabolism <68>; #2# inhibition of the aldehyde-metabolizing enzyme
	modulates NF-kappaB-dependent activation of inflammatory cytokines and
	chemokines in mouse serum, liver, heart, and spleen, overview <74>; #5#
	inhibitor synthesis, overview, enzyme docking study, modeling, no
	inhibition by
	(1,3,3-trioxo-2,3-dihydronaphtho[2,3-d]isothiazol-2-yl)acetic acid and
	2-methyl-1,3,3-trioxo-1,2-dihydronaphtho[1,2-d]isothiazole-4-carboxylic
	acid <77>; #8# molecular modelling, enzyme docking at the active site
	of the enzyme, structure-activity relationships of
	5-arylidene-2,4-thiazolidinediones, an additional aromatic ring or an
	H-bond donor group on the 5-benzylidene ring enhance ALR2 inhibitory
	potency, the presence of a carboxylic anionic chain on N-3 is
	important, and the length of the carboxylic chain is critical,
	overview, no inhibition by 5b
	4-[2,4-dioxo-5-(4-phenoxybenzylidene)thiazolidin-3-yl]-2-butenoic acid
	methyl ester <61>; #8# no inhibition by
	3,5-bis(3,4-dimethoxybenzylidene)-4-piperidone,
	1,5-bis(3,4-dimethoxyphenyl)-1,4-pentadiene-3-one,
	2,5-bis(3,4-dimethoxybenzylidene)cyclopentanone, and
	2,6-bis(3,4-dimethoxybenzylidene)cyclohexanone, at 0.1 mM <56>; #8#
	poor inhibition by
	[2,4-dioxo-5-(4-phenoxybenzyl)thiazolidin-3-yl]acetic acid methyl ester
	<62>; #5# synthesis and structure-activity relationship study of
	inhibitors, overview <76>; #4# Arg312 in ALR1 contributes favourably to
	the binding of 3,5-dichlorosalicylic acid through an electrostatic
	interaction with the inhibitors electronegative halide atom and
	undergoes a conformational change upon tolrestat binding. Tyr116 in
	ALR1 forms electrostatic interactions with the fluorobenzyl moiety of
	minalrestat and the 3- and 4-hydroxy groups on the phenyl ring of
	quercetin. <109>; #5# berberine and palmatine exhibit no RLAR
	inhibitory activities within the test concentration of 0.012.5-0.05
	mg/ml <105>; #5# extract and fractions of the rhizome of Coptis
	chinensis exhibit broad and moderate RLAR inhibitory activities of
	approximately 0.038.9-0.067.5 mg/ml <105>; #5# methanolic and ethanolic
	extracts of Litchi chinensis fruits are potent inhibitors of rat lens
	aldose reductase <117>; #4# not inibited by
	(Z)-2-[2,4-dioxo-5-(4-phenoxybenzylidene)thiazolidin-3-yl]acetamide,
	(Z)-2-[5-(4-methoxybenzylidene)-2,4-dioxothiazolidin-3-yl]acetamide,
	and
	(Z)-2-[5-(3-hydroxy-4-methoxybenzylidene)-2
	4-dioxothiazolidin-3-yl]acetamide <108>; #5# the enzyme activity is not
	affected by 0.1 mM Wy14643 <110>; #5# design and synthesis of pyrrole
	based inhibitors and evaluation as selective aldose reductase
	inhibitors, bioisosterism between a carboxylic acid moiety and that of
	a tetrazole, overview <131>; #4# development of series of highly potent
	and selective
	[3-(4,5,7-trifluoro-benzothiazol-2-ylmethyl)-pyrrolo[2
	3-b]pyridin-1-yl]acetic acid aldose reductase inhibitors. The compounds
	inhibit aldose reductase, but are inactive against aldehyde reductase
	<129>; #4# enzyme active site interactions with the
	3-carboxymethoxy-4-methoxy-phenyl moiety of the inhibitor, binding
	structure, overview <135>; #4# identification of inhibitory compounds
	from Glycyrrhiza uralensis, overview <128>; #5# identification of
	inhibitory compounds from Glycyrrhiza uralensis, overview. Inhibitory
	effect of the compounds on the sorbitol accumulation in rat lenses
	incubated with high glucose <128>; #4# inhibition of the enzyme
	activity also inhibits the expression of the enzyme protein in
	xenograft tissue <141>; #5# inhibitory effect of total lignan from
	fructus Arctii on aldose reductase, ethanolic extract from dry ripe
	fruits of Arctium lappa <143>; #4# structure analysis of a series of
	2,4-thiazolidinediones derivative ALR2 inhibitors, 3D-QSAR molcular
	modeling, detailed overview. A large volume group next to the
	R-substituent will increase the ALR2 inhibitory activity, and adding a
	-CH2COOH substituent at the R-position can generate a compound with
	higher predicted activity <140>; #5# structure-activity relationship of
	a series of coumarins as ALR1 inhibitors, overview. The C6 OH group
	interferes with ALR1 inhibition activity <130>; #5# structure-activity
	relationship of a series of coumarins as ALR2 inhibitors and their
	suppressive effect on the accumulation of galactitol in the rat lens,
	overview. Substitutions in the C7 OH group enhanced the potency toward
	ALR2 <130>; #8# synthesis and evaluation of 2,4-thiazolidinedione
	inhibitors, structure-activity relationships, overview. No inhibition
	by
	(Z)-5-[(4-benzyloxyphenyl)methylidene]-3-(3,3
	3-trifluoro-2-oxopropyl)-2,4-thiazolidinedione <132>; #5# inhibitor
	development, synthesis and molecular docking, overview <148>; #4#
	inhibitor molecular docking study with ALR2, overview <149>; #5#
	inhibitors isolated from Prunus mume flower buds, cultivated in
	Zhejiang province, China, structure analysis, overview <152>; #5#
	synthesis of quinoxalinone derivatives as potent inhibitors of aldose
	reductase, Structure-activity relationship and molecular docking
	studies, overview <146>; #27# analysis of pterin-7-carboxamides as
	aldose reductase inhibitors, evaluation of the inhibitory activity of
	the compounds <159>; #27# design and synthesis of chiral
	2H-chromene-N-imidazolo-imino acid conjugates as aldose reductase
	inhibitors, identification by NMR and mass spectrometry, in vitro
	inhibition screening, molecular docking study, overview <162>; #34#
	design and synthesis of potent and multifunctional aldose reductase
	inhibitors based on quinoxalinones, overview. Phenolic structure is
	installed in the compounds for the combination of antioxidant activity
	and strengthening the ability to fight against diabetic complications,
	radical scavenging activity using the model reaction with the stable
	free radicals of 2,2-diphenyl-1-picrylhydrazyl. Molecular docking study
	using the lidorestat-bound conformation of ALR2, PDB ID 1Z3N <169>;
	#34# flavonoids from Litsea japonica inhibit advanced glycation end
	products formation and rat lense aldose reductase in vitro with IC50
	values of 0.0074-0.072 mM, flavonoid structure determinations by NMR
	spectroscopy, overview. No significant inhibition by 1, 2, afzelin,
	quercitrin, rutin, and lyoniside <173>; #27# identification of aldose
	reductase inhibitors based on carboxymethylated mercaptotriazinoindole
	scaffold, structure-activity relationships, overview <170>; #27,36# no
	inhibition by the triazole
	1-(beta-D-glucopyranosyl)-4-(3,4,5-trihydroxyphenyl)-1,2,3-triazole,
	the amide N-phenylacetyl beta-D-glucopyranosylamine, and the glycosides
	of beta-glucogallin, 2-(3,4,5-trihydroxyphenyl)ethyl
	beta-D-glucopyranoside,
	[1-(3,4,5-trihydroxybenzyl)-1,2,3-triazole-4-yl]methyl
	beta-D-glucopyranoside, and 3-(3,4,5-trihydroxyphenyl)propyl
	beta-D-glucopyranoside, synthesis and evaluation, overview <168>;
	#27,38# partial nonclassical competitive inhibition is exerted by the
	aldose hemiacetal on the reduction of the free aldehyde, aldose
	reductase modulation by hemiacetals, negative cooperative behavior of
	AR acting on L-idose, mechanism of inhibition, kinetic modelling,
	nonclassical competitive model, detailed overview <158>; #34#
	structure-activity relationships study of quinoxalinone derivatives as
	aldose reductase inhibitors. Among them, N1-acetate derivatives have
	significant activity, molecular modeling and docking, overview. Both
	C3-phenethyl and C6-NO2 groups play an important role in enhancing the
	activity and selectivity of the quinoxalinone based inhibitors <163>;
	#38# synthesis, characterization, hypoglycemic and aldose reductase
	inhibition activity of
	arylsulfonylspiro[fluorene-9,5-imidazolidine]-2,4-diones, analysis of
	the Kador-Sharpless model for minimal pharmacophoric requirements for
	an aldose reductase inhibitor, and superposition of target molecules on
	a hypoglycemic pharmacophoric model and a aldose reductase
	pharmacophoric model, overview. Molecular dynamics simulations and
	inhibitor binding model. Effects of the compounds on diabetic BALB/c
	mice <164>)
	<17,34,44,56,60,61,62,68,69,71,74,76,77,105,108,109,110,117,128,129,130
	131,132,135,140,141,143,146,148,149,152,158,159,162,163,164,168,169,170
	173>

///
